Skip Navigation


JAC Advance Access originally published online on December 4, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/1/23    most recent
dkh019v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fang, F.
Right arrow Articles by Yu, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fang, F.
Right arrow Articles by Yu, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 23-25
© 2004 The British Society for Antimicrobial Chemotherapy

Leading Article

Viral receptor blockage by multivalent recombinant antibody fusion proteins: inhibiting human rhinovirus (HRV) infection with CFY196

Fang Fang* and Mang Yu

NexBio, Inc., 6650 Lusk Boulevard, Suite B102, San Diego, CA 92121, USA

Viral receptor blockage by monoclonal antibodies (mAbs) is a common strategy to inhibit viral infection; however, no drug candidate acting by this mechanism has reached the market so far. Analysis of the experimental and clinical data on a receptor-blocking mAb, mAb 1A6, against human rhinovirus (HRV) major receptor intercellular adhesion molecule 1 (ICAM-1) reveals that insufficient avidity of the mAb is probably the key factor to blame for its unsatisfactory clinical efficacy. In this article, we have summarized the recently published work from Perlan Therapeutics, Inc. and others that involves creation of multivalent Fab fusion proteins against the HRV major receptor ICAM-1. The multivalent Fab fusion proteins have exhibited much improved avidities over conventional mAbs, as well as superior HRV inhibition in vitro. This work has led to a promising drug candidate, CFY196, for prevention and treatment of HRV infections. Multivalent recombinant Fab fusion proteins may herald a new generation of potent antiviral receptor blockers and other therapeutic molecules.

Keywords: monoclonal antibodies, multivalent receptor blockers, antiviral

* Corresponding author. Tel: +1-858-452-2631; Fax: +1-858-452-2534; E-mail: ffang{at}nexbio.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
D. Frasca, S. Marchand, F. Petitpas, C. Dahyot-Fizelier, W. Couet, and O. Mimoz
Pharmacokinetics of Ertapenem following Intravenous and Subcutaneous Infusions in Patients
Antimicrob. Agents Chemother., February 1, 2010; 54(2): 924 - 926.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. J. Hall, M. E. Bates, L. Guar, M. Cronan, N. Korpi, and P. J. Bertics
The Role of p38 MAPK in Rhinovirus-Induced Monocyte Chemoattractant Protein-1 Production by Monocytic-Lineage Cells
J. Immunol., June 15, 2005; 174(12): 8056 - 8063.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.